Sign Out
Each vial of powder for concentrate for solution for infusion contains 30 mg or 140 mg of polatuzumab vedotin.
After reconstitution, each mL contains 20 mg of polatuzumab vedotin.
Polatuzumab vedotin is an antibody-drug conjugate composed of the anti-mitotic agent monomethyl auristatin E (MMAE) covalently conjugated to a CD79b-directed monoclonal antibody (recombinant humanized immunoglobulin G1 [IgG1], produced in Chinese Hamster Ovary cells by recombinant DNA technology).
Excipients/Inactive Ingredients: Succinic Acid, Sodium Hydroxide, Sucrose, Polysorbate 20.
Continue with Google